Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome

European Journal of Surgical Oncology

Volumn 40, Issue 5, 2014, Pages 559-566

  Imai, K ^a   Emi, Y ^b   Iyama, K I ^c   Beppu, T ^a   Ogata, Y ^d   Kakeji, Y ^e   Samura, H ^f   Oki, E ^b   Akagi, Y ^g   Maehara, Y ^b   Baba, H ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^d KURUME UNIVERSITY MEDICAL CENTER   (Japan)

^e KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f UNIVERSITY OF THE RYUKYUS   (Japan)

^g KURUME UNIVERSITY HOSPITAL   (Japan)

Author keywords

Bevacizumab; Colorectal liver metastases; Oxaliplatin; Sinusoidal obstruction syndrome; Splenic volume

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; BILIRUBIN; CAPECITABINE PLUS OXALIPLATIN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CLINICAL ARTICLE; COLORECTAL LIVER METASTASIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG USE; FEMALE; HUMAN; LEUKOCYTE COUNT; LIVER METASTASIS; LIVER PROTECTION; LIVER RESECTION; LIVER VENOOCCLUSIVE DISEASE; MALE; MIDDLE AGED; MORBIDITY; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIMARY TUMOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPLEEN SIZE; THROMBOCYTE COUNT;

BEVACIZUMAB; COLORECTAL LIVER METASTASES; OXALIPLATIN; SINUSOIDAL OBSTRUCTION SYNDROME; SPLENIC VOLUME;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGAN SIZE; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; SPLEEN; TREATMENT OUTCOME;

EID: 84897441881     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2013.12.009     Document Type: Article

References (30)

1. J. Leporrier, J. Maurel, and L. Chiche et al. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer Br J Surg 93 2006 465 474
2. G.D. Leonard, B. Brenner, and N.E. Kemeny Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma J Clin Oncol 23 2005 2038 2048
3. S. Manfredi, C. Lepage, and C. Hatem et al. Epidemiology and management of liver metastases from colorectal cancer Ann Surg 244 2006 254 259
4. M.A. Choti, J.V. Sitzmann, and M.F. Tiburi et al. Trends in long-term survival following liver resection for hepatic colorectal metastases Ann Surg 235 2002 759 766
5. T.M. Pawlik, C.R. Scoggins, and D. Zorzi et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases Ann Surg 241 2005 715 722
6. S.A. Shah, R. Bromberg, and A. Coates et al. Survival after liver resection for metastatic colorectal carcinoma in a large population J Am Coll Surg 205 2007 676 683
7. E.J. Morris, D. Forman, and J.D. Thomas et al. Surgical management and outcomes of colorectal cancer liver metastases Br J Surg 97 2010 1110 1118
8. R. Adam, V. Delvart, and G. Pascal et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival Ann Surg 240 2004 644 657
9. J. Scheele Hepatectomy for liver metastases Br J Surg 80 1993 274 276
10. F. Bertolini, N. Malavasi, and L. Scarabelli et al. FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer Br J Cancer 104 2011 1079 1084
11. M.W. Saif Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer World J Gastroenterol 15 2009 3855 3864
12. M.J. Overman, D.M. Maru, and C. Charnsangavej et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury J Clin Oncol 28 2010 2549 2555
13. L. Rubbia-Brandt, V. Audard, and P. Sartoretti et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer Ann Oncol 15 2004 460 466
14. J.N. Vauthey, T.M. Pawlik, and D. Ribero et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases J Clin Oncol 24 2006 2065 2072
15. T. Aloia, M. Sebagh, and M. Plasse et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases J Clin Oncol 24 2006 4983 4990
16. H. Nakano, E. Oussoultzoglou, and E. Rosso et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy Ann Surg 247 2008 118 124
17. D. Tamandl, M. Klinger, and S. Eipeldauer et al. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy Ann Surg Oncol 18 2011 421 430
18. H. Hurwitz, L. Fehrenbacher, and W. Novotny et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
19. D. Ribero, H. Wang, and M. Donadon et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases Cancer 110 2007 2761 2767
20. L. Rubbia-Brandt, G.Y. Lauwers, and H. Wang et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin- associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis Histopathology 56 2010 430 439
21. D. Dindo, N. Demartines, and P.A. Clavien Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey Ann Surg 240 2004 205 213
22. D.E. Kleiner, E.M. Brunt, and M. Van Natta et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease Hepatology 41 2005 1313 1321
23. B. Nordlinger, H. Sorbye, and B. Glimelius et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial Lancet 371 2008 1007 1016
24. O. Soubrane, A. Brouquet, and S. Zalinski et al. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome Ann Surg 251 2010 454 460
25. A.E. van der Pool, H.A. Marsman, and J. Verheij et al. Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases J Surg Oncol 106 2012 892 897
26. J. Ward, J.A. Guthrie, and M.B. Sheridan et al. Sinusoidal obstructive syndrome diagnosed with superparamagnetic iron oxide-enhanced magnetic resonance imaging in patients with chemotherapy-treated colorectal liver metastases J Clin Oncol 26 2008 4304 4310
27. M. Klinger, S. Eipeldauer, and S. Hacker et al. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases Eur J Surg Oncol 35 2009 515 520
28. S.B. Kesmodel, L.M. Ellis, and E. Lin et al. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases J Clin Oncol 26 2008 5254 5260
29. M. D'Angelica, P. Kornprat, and M. Gonen et al. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study Ann Surg Oncol 14 2007 759 765
30. S.K. Reddy, M.A. Morse, and H.I. Hurwitz et al. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases J Am Coll Surg 206 2008 96 106